Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $343,284.91 in Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 227,341 shares of the company’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $1.51, for a total value of $343,284.91. Following the completion of the transaction, the insider directly owned 5,019,151 shares in the company, valued at approximately $7,578,918.01. The trade was a 4.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Monday, October 13th, Gilde Healthcare Cooperatieve sold 47,686 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.54, for a total value of $73,436.44.
• On Friday, October 10th, Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $77,296.95.
• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.56, for a total value of $75,143.64.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.57, for a total value of $45,457.78.

LAVA Therapeutics Stock Performance

LVTX opened at $1.48 on Friday. The company has a market cap of $38.94 million, a PE ratio of -1.41 and a beta of 0.50. The stock has a 50-day moving average of $1.55 and a 200-day moving average of $1.40. LAVA Therapeutics N.V. has a 52-week low of $0.85 and a 52-week high of $2.09.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). On average, research analysts predict that LAVA Therapeutics N.V. will post -1.13 earnings per share for the current year.

Institutional Trading of LAVA Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LVTX. BML Capital Management LLC acquired a new stake in LAVA Therapeutics in the 1st quarter valued at approximately $2,490,000. XTX Topco Ltd acquired a new stake in LAVA Therapeutics in the 1st quarter valued at approximately $31,000. Lepercq De Neuflize Asset Management LLC acquired a new stake in LAVA Therapeutics in the 1st quarter valued at approximately $29,000. Finally, Rangeley Capital LLC acquired a new stake in LAVA Therapeutics in the 2nd quarter valued at approximately $36,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright lowered their price objective on LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating on the stock in a report on Tuesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of LAVA Therapeutics in a report on Wednesday, October 8th. Finally, Jefferies Financial Group lowered LAVA Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $3.00 to $1.50 in a report on Tuesday, August 5th. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, LAVA Therapeutics currently has a consensus rating of “Reduce” and an average target price of $2.69.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.